These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy]. Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267 [TBL] [Abstract][Full Text] [Related]
5. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?]. Pérez A Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585 [No Abstract] [Full Text] [Related]
6. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. Geng Q; Ren J; Chen H; Lee C; Liang W Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):219-26. PubMed ID: 23324122 [TBL] [Abstract][Full Text] [Related]
7. Fenofibrate profiled as the fibrate with additional new data, supporting its use with statins in the European Medicines Agency recommendations. Cardiovasc J Afr; 2011; 22(1):55. PubMed ID: 21298212 [No Abstract] [Full Text] [Related]
8. [Reasons for a combination]. Núñez-Cortés JM Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547 [No Abstract] [Full Text] [Related]
9. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Filippatos TD; Elisaf MS Expert Opin Pharmacother; 2011 Aug; 12(12):1945-58. PubMed ID: 21736529 [TBL] [Abstract][Full Text] [Related]
12. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials. Geng Q; Ren J; Chen H; Lee C; Liang W Curr Med Res Opin; 2013 Mar; 29(3):181-8. PubMed ID: 23323878 [TBL] [Abstract][Full Text] [Related]
13. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557 [TBL] [Abstract][Full Text] [Related]
14. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy. Jialal I; Smith G Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574 [No Abstract] [Full Text] [Related]
16. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164 [TBL] [Abstract][Full Text] [Related]
17. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. Zhao S; Wang F; Dai Y; Lin L; Tong Q; Liao Y; Yin Y; Wang G; Yan Y; Li X; Wang D; Wei P; Cheng X; Xie Q; Sun Y; Fu G; Huang H; Dong Y; Liu J; Yan J; Yan L; Cui S; Liu X; Li Z; Chen H; Hu T; Gong H Int J Cardiol; 2016 Oct; 221():832-6. PubMed ID: 27434354 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520 [TBL] [Abstract][Full Text] [Related]
20. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Khera AV; Qamar A; Reilly MP; Dunbar RL; Rader DJ Am J Cardiol; 2015 Jan; 115(2):178-82. PubMed ID: 25432415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]